Trial Profile
Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Bayer
- 31 Oct 2022 Results( 24-month outcomes) assessing effectiveness of intravitreal aflibercept for diabetic macular edema in the real-world clinical practice setting in Japan published in the Graefes Archive for Clinical and Experimental Ophthalmology
- 12 Sep 2019 Status changed from active, no longer recruiting to completed.
- 20 Mar 2019 Planned End Date changed from 31 May 2020 to 30 Aug 2019.